Salim S Abdool Karim, MBChB, PhD, DSc (honoris causa) is a South African clinical infectious diseases epidemiologist who is widely recognised for his research contributions in HIV prevention and treatment. He is Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA), and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal in Durban, South Africa. He is also Professor of Clinical Epidemiology at the Mailman School of Public Health at Columbia University, Adjunct Professor of Medicine at Weill Medical College of Cornell University and Associate Member of The Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University. His contributions to microbicides for HIV prevention spans two decades and culminated in the CAPRISA 004 tenofovir gel trial which provided proof-of-concept that antiretroviral drugs can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents which have been used in several HIV vaccine candidates and his clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients. He is Chair of the UNAIDS Scientific Expert Panel, as well as a Member of the PEPfAR Scientific Advisory Board, the Scientific Advisory Board for Global Health of the Bill and Melinda Gates Foundation and the WHO Expert Advisory Panel on Sexually Transmitted Infections and HIV. He is an elected Fellow of the World Academy of Sciences, the African Academy of Sciences, the Academy of Science in South Africa and the American Academy of Microbiology. He is a Foreign Associate Member of the Institute of Medicine.
Email: karims1@ukzn.ac.za
Tel: 031 260 8073/4548
Fax: 031 260 2384